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INTRODUCTION
Some crewmembers have experienced changes in their
vision after long-duration spaceflight on the ISS. These
impairments include visual performance decrements,
development of cotton-wool spots or choroidal folds,
optic-disc edema, optic nerve sheath distention, and/or
posterior globe flattening with varying degrees of severity
and permanence. These changes are now used to define
the visual impairment/intracranial pressure (VIIP)
syndrome. It is known that many medications can have
side effects that are similar to VIIP symptoms. Some
medications raise blood pressure, which can affect
intracranial pressure. Many medications that act in the
central nervous system can affect intracranial pressures
and/or vision. About 40% of the medications in the ISS kit
are known to cause side effects involving changes in
blood pressure, intracranial pressure and/or vision. For
this reason, we have begun an investigation of the
potential relationship between ISS medications and their
risk of causing or exacerbating VIIP-like symptoms.
METHODS
The medical literature indicates that pain relievers,
especially non-steroidal anti-inflammatory (NSAID)
medication (like ibuprofen) and glucocorticoids (like
dexamethasone) were among the most likely candidate
medications, and have the focus of initial queries for this
study. Two different data sources were examined.
Data from the general population: The Food and Drug
Administration (FDA) maintains a system for collecting
suspected medication adverse events in their Adverse
Event Reporting System (AER). Patients and medical
professionals may enter data regarding suspected events
and these unconfirmed raw data are available for public
download. In this study, we downloaded 3 years of data
representing over 1 million suspected medication-related
adverse events from January 2009 – December 2011. To
better model the astronaut corps, cases involving
individuals younger than 25 or older than 65 were
removed from our analysis. Similarly, cases involving
cancer, multiple sclerosis or other serious and chronic
conditions were removed. Medications used in cases
associated with VIIP-like symptoms were examined.
PRELIMINARY RESULTS
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Figure 1. Occurrence of VIIP-like Symptoms With Suspected Link to  
Medication Use in the General Population
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C. Dexamethasone
ABSN Abnormal Sensation in Eye
ICP Increased Intracranial Pressure
IOP Increased Intraocular Pressure
ONT Optic Neuritis
ONP Optic Neuropathy
PAP Papilledema
VAR Visual Acuity Reduced
VI Visual Impairment
VF Vitreous Floaters
Table 1. Total occurrences of VIIP-like symptoms
associated with use of each listed medication in the
general population from 2009 - 2012. Data are from the
FDA AERs and thus, indicate occurrence of symptoms
correlated with use of each medication; causality has not
been confirmed. Furthermore, these data do not permit
an estimate of occurrence rate, because there is no
measure of total medication use or medication use
without adverse events.
Figure 3. VIIP-like Symptom Reports Are Reported by both Males and 
Females in their Middle Years
Male
Female
Unspecified
Figure 2. Occurrence of VIIP-like Symptoms With Suspected Link to  
Prednisone Use Among Different Age Groups in the General Population
Figure 1. Possible gender effects of the listed symptoms associated with medication use in the general
population. A, Ibuprofen; B, Hydrocortisone; C, Dexamethasone. Note that incidences are higher among females
for ibuprofen, but higher in males for dexamethasone. While changes in visual acuity and visual impairment are
reported during use of many medications, dexamethasone also had reports of IOP changes.
Figure 2. Occurrences of VIIP-like
symptoms associated with
prednisone use in the general
population, grouped by subject age.
Occurrence of prednisone-associated
VIIP-like symptoms peaked in
females from 36-45 years old and are
higher in males at older ages.
Figure 3. Reports of VIIP-like
symptoms are associated
with ibuprofen use in the
general population. Results
here are shown grouped by age
range. Although, in general,
more females report VIIP-like
adverse events than males,
reports are nearly equivalent in
the 46-55 age group.
INTERIM CONCLUSIONS
The preliminary nature of this report must be
taken into consideration when interpreting
results. Crew cases are limited in number, and
medication usage records lack details that
would be helpful. For this reason, we are
using the FDA AERs as an additional source
of data. This is a extremely large data set, and
while it includes persons who may not model
the astronaut population, the sheer volume of
data may highlight trends to examine in the
crew data. FDA results are compromised by
several factors, chiefly the lack of causal
information regarding each report, but issues
of incomplete data reporting and
polypharmacy also play confounding roles.
However, certain trends may be noted:
• In the general population, use of several
medications is associated with VIIP-like
symptoms, with changes in visual acuity
being the most common.
• In the general population, there may be
gender trends with males over 46 years of
age more likely to experience or report
VIIP-like symptoms associated with
prednisone use.
• In the general population, there may be a
trend toward increased occurrences of
VIIP-like symptoms with ibuprofen use
by males from 36-65 years old; reports
are higher for females from 26-55. For
purposes of comparison, the average age
of crewmembers at their first ISS mission
is 46.6 years (range 37 – 54 years).
Further detailed examination of both data sets
(general population and crew data) may
permit more substantive correlations as this
study progresses.
REFERENCES
Mader, et al., Ophthalmology, 2011; 118(10): 2058-69. 
Kramer  et al., Radiology, 2012; 263(3): 819-27.
Putcha L, et al., Aviat Space Environ Med. 1999 Jul;70(7):705-8. 
ACKNOWLEDGEMENTS
NSBRI intern Joy C. Eckert developed the Microsoft Access
database from FDA AERs and performed initial data analysis.
Chris Miller (Wyle) provided software expertise and Kami Faust
(Wyle) performed much of the data analysis. The author thanks
NASA JSC Lifetime Surveillance of Astronaut Health and
Occupational Health Board for access to crew data and the NASA
JSC Human Research Program for funding.
# AERs with VIIP‐
like symptoms
Ibuprofen 117
Aspirin 180
Acetaminophen 110
Hydrocortisone 8
Dexamethasone 39
Prednisone 192
Pseudoephedrine 12
Promethazine 14
Benadryl 31
Dexedrine 4
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